Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (989)	6/8/2005 9:23:37 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

VICL Moving well on pre-market, up more than 14% so far.<g> It announced a deal with MRK which will give VICL $3M and further "royalty payments". Bernard Vical Licenses Three Cancer Vaccine Targets to Merck Wednesday June 8, 8:30 am ET SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL - News) announced today that Merck & Co., Inc. (NYSE: MRK - News) has exercised three options under a 2003 amendment to an existing research collaboration and license agreement, granting Merck rights to use Vical's patented non-viral gene delivery technology in cancer vaccine applications. As a result of the option exercise, Vical will receive payments of $3.0 million, and further development may lead to milestone and royalty payments to Vical. In addition, Vical has certain co-promotion rights for therapeutic products resulting from the agreement. "Merck was our initial licensee, and a significant contributor toward the validation of Vical's technology in the infectious disease vaccine field," said Vijay B. Samant, Vical's President and Chief Executive Officer. "We are pleased that Merck's ongoing preclinical evaluation of this technology supported the decision to exercise three options, and excited that our technology is part of Merck's cancer vaccine development program." snip biz.yahoo.com It seems the stock will be able to close today above the resistance at $4.<g> bigcharts.marketwatch.com VICL reportedly has about $2,55 in Cash/Share and Debt/Equ. of 0.14 The BV is around $3 In the last 2Qs the revenues have had significant improvement, and although it has continued to burn money at its usual rate, the lossin the Qs was also cut somewhat.( $0.19 vs.$0.35 and $0.32 vs.$0.45/share)